SCHEMBL4458283

SCHEMBL4458283

CS(=O)(=O)c1cccc(N(c2ccc(F)cc2)C(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 3/20 0.44
KCNE1 P15382 1/20 0.44
KCNQ1 P51787 1/20 0.44
KCND3 Q9UK17 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KCNH2 Q12809 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
EPHX2 P34913 1/20 0.40
POLB P06746 2/20 0.39
PTGS2 P35354 1/20 0.38
LRRK2 Q5S007 1/20 0.38
TSHR P16473 1/20 0.38
ALOX5 P09917 1/20 0.38
NPY5R Q15761 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
GRM2 Q14416 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
NFE2L2 Q16236 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4457222 0.90 TAAR1 (0.43) KCNA5TAAR1PTGS2LRRK2GRM2
SCHEMBL4460584 0.89 TAAR1 (0.44) KCNA5TAAR1PTGS2LRRK2GRM2
SCHEMBL4460448 0.88 CYP3A4 (0.44) TAAR1PTGS2LRRK2KDM4CNFE2L2
SCHEMBL4472842 0.86 TAAR1 (0.40) KCNA5TAAR1PTGS2LRRK2GRM2
SCHEMBL4472149 0.86 TAAR1 (0.41) KCNA5TAAR1PTGS2LRRK2GRM2
SCHEMBL4460408 0.85 NFE2L2 (0.42) KCNA5TAAR1PTGS2NFE2L2CYP3A4
SCHEMBL4462676 0.84 PTGS2 (0.41) KCNH2TAAR1PTGS2LRRK2TSHR
SCHEMBL4461909 0.84 TAAR1 (0.39) TAAR1PTGS2LRRK2GRM2KDM4C
SCHEMBL4459549 0.84 TSHR (0.46) KCNA5L3MBTL1KCNH2TAAR1PTGS2
SCHEMBL4472068 0.84 TAAR1 (0.39) KCNA5TAAR1PTGS2LRRK2GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US claimed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP claimed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO claimed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030043-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 KCNA5 11/4885KCNE1 23/4885KCNQ1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.